Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Skinvisible Pharmaceuticals expands its obesity patent application for transdermal drug delivery using Invisicare technology. The innovation enhances systemic absorption of GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors, offering a needle-free alternative. Skinvisible seeks partners to bring this breakthrough to market.
